Indoco Remedies

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE873D01024
  • NSEID: INDOCO
  • BSEID: 532612
INR
251.70
-0.55 (-0.22%)
BSENSE

Dec 05

BSE+NSE Vol: 17.67 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
SMS Pharma.
Amrutanjan Healt
IOL Chemicals
Unichem Labs.
Advanced Enzyme
Indoco Remedies
Novartis India
Morepen Labs.
Solara Active
Hikal
Panacea Biotec
Why is Indoco Remedies Ltd ?
1
Low ability to service debt as the company has a high Debt to EBITDA ratio of 4.18 times
  • Low ability to service debt as the company has a high Debt to EBITDA ratio of 4.18 times
  • The company has been able to generate a Return on Equity (avg) of 9.06% signifying low profitability per unit of shareholders funds
2
Poor long term growth as Operating profit has grown by an annual rate -185.53% of over the last 5 years
3
The company has declared Negative results for the last 12 consecutive quarters
  • INTEREST(Latest six months) At Rs 50.68 cr has Grown at 48.67%
  • ROCE(HY) Lowest at -2.14%
  • DEBT-EQUITY RATIO(HY) Highest at 1.02 times
4
Risky - Negative Operating Profits
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of -21.87%, its profits have fallen by -552.7%
5
Falling Participation by Institutional Investors
  • Institutional investors have decreased their stake by -0.77% over the previous quarter and collectively hold 19.41% of the company
  • These investors have better capability and resources to analyse fundamentals of companies than most retail investors
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Indoco Remedies for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Indoco Remedies
-21.65%
-0.47
46.16%
Sensex
4.83%
0.41
11.83%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
8.16%
EBIT Growth (5y)
-185.53%
EBIT to Interest (avg)
6.71
Debt to EBITDA (avg)
3.78
Net Debt to Equity (avg)
1.00
Sales to Capital Employed (avg)
1.11
Tax Ratio
8.98%
Dividend Payout Ratio
14.04%
Pledged Shares
0
Institutional Holding
19.41%
ROCE (avg)
11.45%
ROE (avg)
9.06%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
34
Price to Book Value
2.36
EV to EBIT
-69.19
EV to EBITDA
45.87
EV to Capital Employed
1.68
EV to Sales
1.91
PEG Ratio
NA
Dividend Yield
0.08%
ROCE (Latest)
-2.43%
ROE (Latest)
-11.33%
Loading Valuation Snapshot...
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Bullish
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

4What is working for the Company
NET SALES(Q)

Highest at Rs 484.67 cr

PBDIT(Q)

Highest at Rs 43.05 cr.

PAT(Q)

Highest at Rs -7.40 cr.

EPS(Q)

Highest at Rs -0.86

-12What is not working for the Company
INTEREST(Latest six months)

At Rs 50.68 cr has Grown at 48.67%

ROCE(HY)

Lowest at -2.14%

DEBT-EQUITY RATIO(HY)

Highest at 1.02 times

DEBTORS TURNOVER RATIO(HY)

Lowest at 3.73 times

Loading Valuation Snapshot...
Here's what is working for Indoco Remedies
Net Sales - Quarterly
Highest at Rs 484.67 cr
in the last five quarters
MOJO Watch
Near term sales trend is positive

Net Sales (Rs Cr)

Operating Profit (PBDIT) - Quarterly
Highest at Rs 43.05 cr.
in the last five quarters
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (Rs Cr)

Profit After Tax (PAT) - Quarterly
Highest at Rs -7.40 cr.
in the last five quarters
MOJO Watch
Near term PAT trend is positive

PAT (Rs Cr)

Earnings per Share (EPS) - Quarterly
Highest at Rs -0.86
in the last five quarters
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (Rs)

Here's what is not working for Indoco Remedies
Interest - Latest six months
At Rs 50.68 cr has Grown at 48.67%
over previous Half yearly period
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (Rs cr)

Debt-Equity Ratio - Half Yearly
Highest at 1.02 times and Grown
each half year in the last five half yearly periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Debtors Turnover Ratio- Half Yearly
Lowest at 3.73 times
in the last five half yearly periods
MOJO Watch
Company's pace of settling its Debtors has slowed

Debtors Turnover Ratio